Bladder cancer has a cure rate of over 90% when detected early, but it has a high recurrence rate of 70%, necessitating continuous monitoring. Late detection often requires major surgeries, such as ...
Bladder cancer has a cure rate of over 90% when detected early, but it has a high recurrence rate of 70%, necessitating continuous monitoring. Late detection often requires major surgeries such as ...
Cellens, a Boston, MA-based cancer diagnostics startup, has raised a $6.5 million seed round. The company is developing a mechanobiology and AI-driven platform, BioFeel, for non-invasive cancer ...
The Food and Drug Administration has approved a new LabCorp test that will enhance treatment for people suffering from bladder cancer, the Burlington-based company announced. The Ventana PD-L1, a ...
(MENAFN- EIN Presswire) EINPresswire/ -- Cellens, Inc., a cancer diagnostics company pioneering a new mechanobiology and AI-driven platform, BioFeelTM, for non-invasive cancer detection, has raised a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results